Newsletter Archive

  1. 02.22.17 -- Launching A New Drug In A Maturing Market — Lessons Learned From New COPD Entrants
    2/22/2017
    02/22/17 BioProcess Online Newsletter
  2. 02.20.17 -- Era Of 'Brutal Disruption' – 6 Rules To Succeed
    2/20/2017
    02/20/17 BioProcess Online Newsletter
  3. 02.15.17 -- Examining The FDA’s New Guidance On Quality Agreements
    2/15/2017
    02/15/17 BioProcess Online Newsletter
  4. 02.13.17 -- Designing The Cell Therapy Facility Of The Future
    2/13/2017
    02/13/17 BioProcess Online Newsletter
  5. 02.08.17 -- Intro To The LAL Assay For Pyrogen Testing Of Parenteral Products
    2/8/2017
    02/08/17 BioProcess Online Newsletter
  6. 02.06.17 -- BPOG On Human Performance Tools & Just Culture In Biopharma Operations
    2/6/2017
    02/06/17 BioProcess Online Newsletter
  7. 02.01.17 -- DoD Opens Advanced Biologics Manufacturing Facility For Private, Public Use
    2/1/2017
    02/01/17 BioProcess Online Newsletter
  8. 01.30.17 -- Analysis Of FDA FY2016 Drug GMP Warning Letters
    1/30/2017
    01/30/17 BioProcess Online Newsletter
  9. 01.25.17 -- Is An FDA Pre-IND Meeting Worth It? How To Decide & How To Prepare
    1/25/2017
    01/25/17 BioProcess Online Newsletter
  10. 01.23.17 -- CAPA Effectiveness Checks 101: How To Verify Your Action Plans Are Successful
    1/23/2017
    01/23/17 BioProcess Online Newsletter